Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2017 | 1 |
2019 | 1 |
2021 | 1 |
2022 | 1 |
2023 | 2 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
Page 1
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer.
N Engl J Med. 2023 Jun 8;388(23):2145-2158. doi: 10.1056/NEJMoa2216334. Epub 2023 Mar 27.
N Engl J Med. 2023.
PMID: 36972026
Clinical Trial.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group.
Martin M, et al.
Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13.
Lancet Oncol. 2017.
PMID: 29146401
Clinical Trial.
Item in Clipboard
[Immunotherapy for patients with malignant melanoma and brain metastases].
Simonsen LT, Schmidt AMS, Øllegaard TH, Svane IM, Bastholt L, Luczak AA, Schmidt H.
Simonsen LT, et al. Among authors: luczak aa.
Ugeskr Laeger. 2019 Jun 10;181(24):V01190057.
Ugeskr Laeger. 2019.
PMID: 31267950
Free article.
Review.
Danish.
Item in Clipboard
Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panel.
Kisistók J, Christensen DS, Rasmussen MH, Duval L, Aggerholm-Pedersen N, Luczak AA, Sorensen BS, Jakobsen MR, Oellegaard TH, Birkbak NJ.
Kisistók J, et al. Among authors: luczak aa.
Melanoma Res. 2023 Oct 1;33(5):364-374. doi: 10.1097/CMR.0000000000000903. Epub 2023 Jun 12.
Melanoma Res. 2023.
PMID: 37294123
Free PMC article.
Item in Clipboard
Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma.
Pedersen JG, Sokac M, Sørensen BS, Luczak AA, Aggerholm-Pedersen N, Birkbak NJ, Øllegaard TH, Jakobsen MR.
Pedersen JG, et al. Among authors: luczak aa.
Cancers (Basel). 2022 Jul 9;14(14):3342. doi: 10.3390/cancers14143342.
Cancers (Basel). 2022.
PMID: 35884403
Free PMC article.
Item in Clipboard
Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study.
Fink M, Vittrup AS, Bastholt L, Svane IM, Donia M, Luczak AA, Ruhlmann CH, Guldbrandt LM, Koehler UH, Winther ML, Ellebaek E, Haslund CA, Schmidt H.
Fink M, et al. Among authors: luczak aa.
Cancers (Basel). 2021 Nov 5;13(21):5550. doi: 10.3390/cancers13215550.
Cancers (Basel). 2021.
PMID: 34771712
Free PMC article.
Item in Clipboard
Cite
Cite